The Bid & Ask

Quotations, Dispatches, and the Daily Tape

Friday, August 14, 2026

Subject of the day

MRK

Concerning the House

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

United States · www.merck.com

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$60.12B+5.9%
Net income$18.25B+2.2%
Cash from ops$16.47B+12.9%
Quotation

$135.55

+2.63 (+2.0%)

52w hi$135.55
52w lo$75.83
Vol6.91M
As ofAug 13
The Verdict

Hold

Our score +0.28

Short+0.21
Medium+0.40
Long+0.16

computed 2026-08-13

By the Numbers

Merck & Co., Inc.

Healthcare · Drug Manufacturers - General

Market cap$334.43B
Enterprise value$374.76B
Trailing P/E108.44x
Forward P/E14.20x
EV / EBITDA12.98x
P / S (ttm)5.02x
Profit margin4.8%
Return on equity7.0%
Revenue growth+5.1%
Earnings growth
Debt / equity128.41
Risk Metrics
Beta vs SPX0.28
Corr SPX0.17
Annual vol27.3%
Annual ret+12.4%
Sharpe0.45
Max DD-38.1%

Window: 504 trading days (504 obs)

Layer Breakdown
LayerRawContribution
Fundamental+0.14
Sector+0.12
Technical+0.18
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-08-13

Recent Sessions
DateOpenHighLowCloseVol
Aug 13$133.86$135.68$133.05$135.556.91M
Aug 12$130.25$134.06$128.91$132.9210.45M
Aug 11$129.93$132.84$129.70$130.426.34M
Aug 10$128.29$130.98$128.24$130.926.01M
Aug 7$127.84$128.75$126.68$128.587.35M